Foghorn Therapeutics Inc (FHTX) — Cash Flow Reinvestment Rate

Latest as of March 2022: 0.59x

Foghorn Therapeutics Inc (FHTX) has a Cash Flow Reinvestment Rate of 0.59x as of March 2022, reinvesting $159.41 Million (capex $247.00K plus investments $-159.16 Million) from operating cash flow of $271.53 Million. Explore FHTX cash flow conversion to assess how effectively this company generates cash.

Reinvestment Rate

0.59x

(Capex + Investments) / Operating CF

Total Reinvested

$159.41 Million

Capex + Investments

Operating Cash Flow

$271.53 Million

USD

Capital Expenditures

$247.00K

USD

Foghorn Therapeutics Inc Cash Flow Reinvestment Rate (2022–2022)

Historical reinvestment intensity for Foghorn Therapeutics Inc across 1 annual periods. Explore Foghorn Therapeutics Inc cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.

Annual Cash Flow Reinvestment Rate for Foghorn Therapeutics Inc (2022–2022)

Year-by-year capital reinvestment analysis for Foghorn Therapeutics Inc. For live market cap and broader valuation context, see Foghorn Therapeutics Inc stock valuation.

Year	Reinvestment Rate	Total Reinvested (USD)	Operating CF	Capex	YoY Change
2022	1.26x	$244.32 Million	$193.61 Million	$1.21 Million	—

Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow